ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1503

Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US

Huifeng Yun1, Shuo Yang2, Sofia Pedro3, Jeffrey Curtis4 and Kaleb Michaud5, 1Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3National Data Bank for Rheumatic Diseases, Wichita, KS, 4Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5University of Nebraska Medical Center, Omaha, NE

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rates of adult vaccination are low in patients with autoimmune disease despite broad recommendations for many years. In the U.S., pneumococcal vaccination is recommended for people age 65 or older or with a risk factor (e.g. immunosuppression); herpes zoster (HZ) vaccination is recommended for adults aged 60 years and older, and influenza vaccination has been recommended for all persons aged ≥ 6 months. Despite many studies showing patients with rheumatic diseases or treated with immunosuppressive medications are at an increased risk of infections, but factors associated with receive recommended immunizations are not well known. We evaluated the pattern of pneumococcal, HZ, and seasonal influenza vaccination and factors associated with receiving these vaccinations among patients participating in a national US. registry.

Methods: We examined patient self-reported survey responses among participants in the National Data Bank for Rheumatic Diseases (NDB) from 2006-2015. After excluding patients who never answered vaccine questions, all adult patients in the registry with a rheumatologist-diagnosed rheumatic disease were eligible for analysis. Patients <60 years old or who enrolled after 2007 were excluded from the analysis of the HZ vaccine use due to incomplete vaccine history. Vaccine administrations and potential confounders were time-varying and updated at the time of each 6 month survey. For pneumococcal and HZ vaccine, follow-up started at the first survey that all required criteria were met and ended at the earlier date of either vaccination, death, or exited the registry. For influenza, patients were allowed to have multiple vaccinations. A generalized estimating equation model with repeated measures was used to evaluate the factors associated with receipt of each vaccine.

Results: Among 21,522 patients (72.8% with RA, 16.9% with OA, 10.1% with Fibromyalgia, 7% with SLE, patients were allowed to have multiple conditions) who were eligible for pneumococcal and influenza vaccination analysis, we identified 9,162 and 84,991 vaccinations, respectively. Of the cohort, 74.7% had at least one influenza vaccination during the 10 years of study period.The proportion of patients receiving the influenza vaccine in each year is on the average of 60%. ). 9,867(45.8%) patients never had pneumococcal vaccination and 5,438 (25.2%) patients never had influenza vaccination.  Of 11,947 eligible patients for HZ vaccine analysis, 1,724 (14.4%) received the HZ vaccine over a median (IQR: 6 years) of 4.5 years of follow-up.  After multivariable adjustment, older age, African American race, biologic use, cardiovascular disease, and prior hospitalization were significantly associated with all three vaccinations.  Factors associated with each vaccine vary (see Table). 

Conclusion: Overall rates of pneumococcal, HZ, and influenza vaccinations were low among patients with rheumatic diseases. For each type of vaccination, more efforts on different associated factors are needed to improve the vaccination rate. Table: Multivariable factors associated with vaccination among patients with rheumatic diseases in the NDB

Characteristics†

Vaccination

Pneumococcal

(n=21,522)

Herpes Zoster

(n=11,947)

Influenza

(n=21,522)

Age, year

1.02 (1.02, 1.03)

1.0 (0.99, 1.0)

1.03 (1.03, 1.04)

Male sex

1.01 (0.94, 1.08)

1.10 (0.98, 1.24)

0.93 (0.89, 0.98)

Ethnicity

Caucasian

Ref (1.0)

Ref (1.0)

Ref (1.0)

African American

1.24 (1.07, 1.43)

0.65 (0.45, 0.93)

0.82 (0.73, 0.92)

Hispanic

1.27 (1.06, 1.51)

0.92 (0.60, 1.42)

0.94 (0.82, 1.08)

Asian

1.11 (0.78, 1.58)

1.79 (1.10, 2.92)

0.95 (0.74, 1.23)

Other

1.10 (0.76, 1.57)

0.45 (0.15, 1.37)

0.89 (0.69, 1.15)

Alcohol use

0.84 (0.48, 1.48)

1.85 (0.77, 4.41)

1.06 (0.87, 1.30)

Smoker, current

1.02 (0.91, 1.14)

0.62 (0.47, 0.84)

0.78 (0.72, 0.85)

Rheumatoid arthritis

1.21 (1.03, 1.43)

0.75 (0.56, 1.01)

1.05 (0.93, 1.19)

Osteoarthritis

1.15 (0.99, 1.34)

0.97 (0.75, 1.24)

1.00 (0.90, 1.12)

Fibromyalgia

1.00 (0.87, 1.15)

0.95 (0.78, 1.16)

0.87 (0.79, 0.97)

Lupus

1.52 (1.31, 1.75)

0.83 (0.61, 1.13)

1.35 (1.22, 1.50)

Biologics

1.17 (1.10, 1.24)

0.53 (0.47, 0.61)

1.18 (1.13, 1.22)

Non-biologic DMARDs

1.06 (0.99, 1.13)

0.76 (0.68, 0.86)

0.99 (0.95, 1.03)

Glucocorticoids

None

Ref (1.0)

Ref (1.0)

Ref (1.0)

≤7.5 mg/day

1.12 (1.05, 1.20)

0.77 (0.66, 0.90)

0.98 (0.94, 1.02)

>7.5 mg/day

1.13 (1.01, 1.27)

0.83 (0.64, 1.07)

0.97 (0.92, 1.03)

Nursing home residency

2.15 (1.79, 2.57)

0.81 (0.55, 1.21)

1.10 (1.01, 1.21)

Hospitalization

0.74 (0.55, 0.99)

0.38 (0.17, 0.81)

0.70 (0.62, 0.78)

Comorbidities

Cardiovascular

1.18 (1.11, 1.25)

1.20 (1.08, 1.32)

1.23 (1.18, 1.28)

Liver

0.89 (0.70, 1.13)

0.94 (0.59, 1.51)

0.96 (0.87, 1.05)

Lung

1.55 (1.40, 1.72)

0.90 (0.74, 1.10)

1.16 (1.09, 1.22)

Stroke

1.15 (0.81, 1.62)

0.58 (0.27, 1.23)

0.94 (0.82, 1.08)

Diabetes

1.22 (1.11, 1.33)

0.99 (0.85, 1.15)

1.14 (1.09, 1.21)

Cancer

1.10 (0.93, 1.31)

0.80 (0.59, 1.09)

0.99 (0.93, 1.06)

Pneumonia

1.33 (1.18, 1.51)

N/A

N/A

Zoster

N/A

2.63 (2.05, 3.36)

N/A

Influenza

N/A

N/A

1.01 (0.96, 1.05)

†Except male sex and ethnicity, all other factors were time-varying and updated on an average of 6 months


Disclosure: H. Yun, Amgen, 2; S. Yang, None; S. Pedro, None; J. Curtis, Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 2,Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 5; K. Michaud, Pfizer Inc, 3.

To cite this abstract in AMA style:

Yun H, Yang S, Pedro S, Curtis J, Michaud K. Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patterns-and-factors-associated-with-immunization-among-adult-patients-with-rheumatic-diseases-in-the-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-and-factors-associated-with-immunization-among-adult-patients-with-rheumatic-diseases-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology